| Evercore ISI Analyst Gives Highlights From Vertex's Orkambi Call | |
| | |
|
In a report published Friday, Evercore ISI analyst Mark Schoenebaum mentioned that the Orkambi approval ROW of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is on track with the EMA approval expected later in 2015.
According to the Evercore ISI report, "Royalties... Will move into low double digits with higher sales total for Kalydeco plus Orkambi (but... with both commercial milestone payments for Orkambi possibly coming due this year, when accounted for in cost of revenues... VRTX will in effect likely reach double digit royalties this year and then continue - although next year and years going forward expected double digit royalties simply due to higher CF sales)."
The analyst believes that the biggest driver "gross to net" for the company's Orkambi candidate is that 35-40 percent of the population using it is Medicaid, while for Kalydeco the Medicaid population makes up about low to mid 20 percent of the users.
The company's VX-661 program is on track and the Het-min trial is expected to start soon. "VRTX has regular FDA interactions and screening for US portion of trial already complete," Schoenebaum mentioned.
Latest Ratings for VRTX
Date | Firm | Action | From | To |
---|
Jun 2015 | RBC Capital | Maintains | | Outperform | Apr 2015 | Citigroup | Maintains | | Buy | Apr 2015 | Oppenheimer | Assumes | | Perform |
View More Analyst Ratings for VRTX
View the Latest Analyst Ratings
See more from Benzinga © 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
|
|
| |
ProfileMarket IndicatorsVALUE : Projects & res.Press releasesAnnual reportRISK : Asset profileContact Cpy |
Vertex Pharma is based in United states of america. Vertex Pharma is listed in United States of America. Its market capitalisation is US$ 120.0 billions as of today (€ 109.7 billions). Its stock quote reached its lowest recent point on March 12, 2004 at US$ 10.00, and its highest recent level on October 11, 2024 at US$ 481.71. Vertex Pharma has 249 070 000 shares outstanding. |